Navigation Links
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
Date:11/6/2008

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2009, ended September 30, 2008. Total revenue for the quarter was $5,090,000 compared to total revenue of $5,352,000 for the second quarter of fiscal year 2008 ended September 30, 2007. Total revenue was comprised of product revenue and royalty and research revenue. Product revenue, comprised of Protein A revenue, for the second quarter of fiscal year 2009 was $2,984,000 and royalty and research revenue was $2,106,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R).

Operating expenses for the second quarter of fiscal year 2009 were $5,414,000 compared to $4,752,000 for the same time period in fiscal year 2008. This increase in operating expenses of $662,000 was primarily the result of increased spending associated with our Phase 3 clinical trial of RG1068 for pancreatic imaging, and preparations for our Phase 2b clinical trial of RG2417 for bipolar depression, as well as increased research and development costs associated with our efforts to identify a clinical candidate for Friedreich's ataxia. These increases in spending were partially offset by reductions in selling, general and administrative expenses, most notably a decrease in legal expenses.

The net income for the second quarter of fiscal year 2009 was $142,000 or $0.00 per diluted share, compared to net income for the second quarter of fiscal year 2008 of $40,306,000 or $1.29 per diluted share. The prior year results were favorably impacted by a $40,170,000 gain from the settlement in the litigation with ImClone Systems, Inc. during fiscal year 2008. Cash, cash equivalents
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
3. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
4. Repligen Announces Share Repurchase Program
5. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
6. Repligen Elects Earl Henry, M.D. to the Board of Directors
7. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
8. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
9. Stereotaxis Reports Third Quarter 2008 Financial Results
10. Volcano Reports 40 Percent Growth in Quarterly Revenues
11. Dialysis Corporation of America Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... people with type 1 version of disease , WEDNESDAY, Aug. ... proteins may contribute to type 1 diabetes, Canadian researchers say. ... found that nearly half had immune system T-cells that overreacted ... abnormal immune response. , "The immune system has to find ...
... but actual amount still small , WEDNESDAY, Aug. 26 (HealthDay ... radiation Americans would otherwise be exposed to, new research shows. ... three-quarters of the exposure, and more than 80 percent of ... Fazel, senior author of a study appearing in the Aug. ...
... contribute to drug resistance in non-small cell lung cancer ... access journal BMC Cancer found good correlation ... and resistance and actual in vitro chemosensitivity. Ian ... team of researchers who assessed the chemosensitivity of a ...
... , DES MOINES, Iowa, Aug. 26 Briggs, the ... solutions to long term care facilities, today announced a unique program to ... certified nursing homes. , , Briggs, new ... in response to the five-star rating system implemented late last year by ...
... ... in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October ... ... Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival ...
... 26 With this morning,s passing of Massachusetts Senator Ted Kennedy ... it could lead to quicker diagnoses for others affected by the ... In 2005, Grundner established The Kelly Heinz-Grundner Brain Tumor Foundation ... his position as Senior Vice President at JPMorgan Chase to dedicate ...
Cached Medicine News:Health News:Medical Scans a Significant Source of Radiation 2Health News:Medical Scans a Significant Source of Radiation 3Health News:Briggs Program Improves Care in Nation's Nursing Homes 2Health News:Briggs Program Improves Care in Nation's Nursing Homes 3Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 2Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 3
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... 31, 2011 AAIPharma Services Corp., a leading ... announced today the promotion of Dean Shirazi, Ph.D., ... the position effective April 4, 2011. ... Shirazi, who joined AAIPharma in June 1992 as ...
... Reportlinker.com announces that a new market research report ... Molecular Diagnostics in Infectious Disease Testing ... This TriMark Publications report describes the specific segment ... molecular diagnostics testing for infectious disease. In the ...
Cached Medicine Technology:AAIPharma Services Announces Promotion of Dean Shirazi 2Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 2Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 3Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 4Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 5Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 6Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 7Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 8Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 9Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 10Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 11Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 12Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 13Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 14Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 15Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 16Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 17Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 18
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
... The 1100RS Spectrophotometers ... economical. Great for use ... laboratories, including educational, clinical, ... Options include COD vial ...
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
Medicine Products: